Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Kiniksa Pharmaceuticals GmbH is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current activity is focused on this 1 pending matter. Practitioners should note that the 1 distinct art unit involved indicates a specialized focus within the biotechnology field. The concentration of the portfolio means that the company's immediate patent strategy is concentrated on 1 point of contact within the patent office. This allows for a targeted approach to prosecution.
The busiest examiner is ESSEX, LAURA ANN, who is responsible for 1 pending office action. Because there is 1 pending office action in total, this 1 examiner is the only one currently reviewing applications for the company. The results of this 1 prosecution will determine the company's immediate success in this technology area. This centralization means that the company's immediate patent prospects are entirely subject to the review and requirements of this 1 individual. Building a clear and persuasive record with ESSEX, LAURA ANN is the primary task for the company's current prosecution efforts. Practitioners can focus exclusively on the preferences of this 1 examiner to advance the 1 pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 1 | 60.0% | +35.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19532470 | TREATMENT OF RECURRENT PERICARDITIS BY DELIVERY OF ANTI-INTERLEUKIN-1 RECEPTOR ANTIBODY | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19532470 | TREATMENT OF RECURRENT PERICARDITIS BY DELIVERY OF ANTI-INTERLEUKIN-1 RECEPTOR ANTIBODY | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | — | Pending | Feb 06, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKiniksa Pharmaceuticals GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Laura Ann Essex has the most, with 1 of Kiniksa Pharmaceuticals GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
